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This observational pilot study was designed to test the hypothesis that blood-based DNA 
methylation levels of endoglin (ENG) and transforming growth factor beta receptor 2 (TGFβR2) 
gene promoter regions differ significantly when comparing women with clinically-overt 
preeclampsia to normotensive pregnant women matched on key variables.  A 1:1 frequency 
matched case-control candidate gene design was used to evaluate ENG and TGFβR2 gene 
promoter methylation levels.  Methylation data were collected using the EpiTect Methyl II 
quantitative Polymerase Chain Reaction (PCR) Assay (Qiagen® Inc., Germantown, Maryland).  
The promoter region CpG islands evaluated included ENG (CpG Island 114642) and TGFβR2 
(CpG Island 110111).  Genomic DNA was extracted from maternal peripheral white blood cells  
via protein precipitation. The sample included n=22 preeclampsia cases 1:1 frequency matched 
to n=22 normotensive controls on gestational age at sample collection (± 2 weeks), smoking 
status, and labor status at sample collection.  All participants were Caucasian and nulliparous.  
Preeclampsia was diagnosed based on blood pressure, protein, and uric acid criteria.  Parametric 
and nonparametric analyses were utilized to compare demographic and clinical characteristics 
between cases and controls. A non-parametric approach (Mann-Whitney U) was utilized to 
compare methylation levels for both candidate genes between cases and controls. Average 
methylation levels for both ENG (Cases [M±(SD)]= 6.54% ± 4.57; Controls= 4.81% ± 5.08; 
p=0.102) and TGFβR2 (Cases= 1.5% ± 1.37; Controls= 1.7% ± 1.4; p= 0.695) promoter CpG 
islands did not significantly differ between cases and controls.  The role that the ENG pathway 
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plays in preeclampsia pathogenesis is not fully understood.  Evaluation of ENG pathway blood-
based DNA methylation levels will better inform us of the potential role that ENG and TGFβR2 
DNA methylation plays in preeclampsia pathophysiology, including the maternal response to 
placental dysfunction.  Although this study did not reveal detectable differences in blood-based 
DNA methylation levels of ENG and TGFβR2 gene promoters during clinically-overt 
preeclampsia, additional epigenetic studies with larger sample sizes are needed to enhance our 
understanding of preeclampsia pathophysiology and to inform the development of prevention, 
detection (e.g. biomarkers), and treatment modalities that improve maternal and fetal health 
outcomes.  
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1.0  BACKGROUND AND SIGNIFICANCE 
Preeclampsia is a multi-system, pregnancy-specific disorder that affects approximately three to 
five percent of pregnancies (Ananth, Keyes, & Wapner, 2013; Abalos, Grosso, Chou & Say, 
2013) and is significantly associated with poor health outcomes for both the mother and the 
fetus/infant (Hypertension in pregnancy. Report of the American College of Obstetricians and 
Gynecologists' Task Force on Hypertension in Pregnancy, 2013). Maternal complications and 
signs/symptoms of preeclampsia include severe headaches, changes in vision, coagulation 
problems related to thrombocytopenia, respiratory dysfunction, renal and hepatic failure, and 
heart disease.  Moreover, preeclampsia can lead to premature birth, placental abruption, 
intrauterine growth restriction, low birthweight, or death of the mother and/or baby (Abalos et 
al., 2014; Creanga et al., 2015; Duley, 2009; Goldenberg, Culhane, Iams, & Romero, 2008; 
Kuklina, Ayala, & Callaghan, 2009; Mor et al., 2016).  In the United States, three out of 20 
premature births can be attributed to unmanaged preeclampsia (March of Dimes, 2016).  
Furthermore, the mother and child are also at increased risk for future cardiovascular dysfunction 
remote from pregnancy (Brown et al., 2013; Davis et al., 2012; Timpka et al., 2016; Wu et al., 
2017). 
Preeclampsia is characterized as new onset hypertension accompanied by proteinuria, or 
signs of multisystem involvement in the absence of proteinuria, after 20 weeks’ gestation in a 
previously normotensive woman (Hypertension in pregnancy. Report of the American College of 
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Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy, 2013).   
Preeclampsia is seen more frequently in women who are nulliparous, pregnant with multiples, or 
are much younger or older than the ideal age for pregnancy (Anderson, Ralph, Wright, Linggi, & 
Ohm, 2014).  Although preeclampsia is a significant cause of maternal and infant morbidity and 
mortality, the pathophysiology is not completely understood, creating a barrier to predicting and 
preventing its development (Chaiworapongsa, Chaemsaithong, Yeo, & Romero, 2014).  
Furthermore, the only known cure for preeclampsia is delivery of the placenta.  In order to screen 
for and prevent preeclampsia, the underlying disorder must be better understood, and in turn, 
efforts can be directed towards the development of preventative, screening, and treatment 
modalities that aim to improve the health outcomes of women and their newborns (Hypertension 
in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on 
Hypertension in Pregnancy, 2013).   
Although it is believed that the development of preeclampsia stems from abnormalities in 
spiral artery transformation, placental implantation, and an unfavorable maternal response, the 
causes of these abnormalities have not been fully elucidated (Chaiworapongsa et al., 2014).  This 
lack of knowledge has hampered the ability to prevent preeclampsia, detect preeclampsia before 
it becomes clinically overt, and treat preeclampsia.  Studies looking at gene pathways that are 
involved with angiogenesis in the nervous system, cardiovascular system, and others have been 
completed, but a biomarker of preeclampsia has not been identified (Anderson et al., 2014; 
Anderson & Schmella, 2017; Ge et al., 2015; Roberts, 2018; White et al., 2013; White et al., 
2016; Ye et al., 2016). ENG and TGFβR2 have been recognized as proteins present on 
proliferating vascular endothelial cells and placental syncytiotrophoblasts that play a role in the 
development of vascular disease, including preeclampsia (ten Dijke, Goumans, & Pardali, 2008).   
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ENG is a receptor protein encoded by the endoglin gene that is expressed on proliferating 
vascular endothelial cells and trophoblast cells of the placenta (Caniggia et al., 1997; ten Dijke, 
Goumans, & Pardali, 2008).  ENG is a co-receptor of the transforming growth factor beta 
(TGFβ) signaling system that is involved in cell proliferation, differentiation, motility, and 
apoptosis (ten Dijke, Goumans, & Pardali, 2008).  Along this pathway, ENG regulates vascular 
tone and angiogenesis and regulates placental implantation/spiral artery remodeling (Caniggia et 
al., 1997; Jerkic et al., 2004; Toporsian et al., 2005).  
TGFβR2 is another receptor protein that is a member of the TGFβ receptor signaling 
pathway that is expressed on the trophoblast of the placenta and vascular endothelial cells 
(Caniggia et al., 1997; Venkatesha et al., 2006).  TGFβR2 is involved in vascular morphogenesis 
and in preventing endothelial cells from growing in an uncontrolled manner, whose signals are 
regulated and modified by ENG (Caniggia et al., 1997; Genetics Home Reference, 2018; ten 
Dijke, Goumans, & Pardali, 2008).  In preeclampsia, vascular homeostasis is disrupted and 
placental implantation/spiral artery remodeling is often inadequate, which provides biologic 
plausibility for the study of ENG and TGFβR2. 
There are multiple lines of evidence that support a role for the endoglin pathway in the 
development of preeclampsia. First, the soluble form of endoglin (sENG), which is thought to be 
generated from the cleavage of membrane-bound ENG from the placenta and released into the 
maternal circulation, is elevated in the maternal circulation of women before clinically-overt 
preeclampsia (Levine et al., 2006; Rana et al., 2007).  When present in the maternal circulation, 
it is thought that sENG interferes with downstream signaling along the TGFβ pathway 
(Venkatesha et al., 2006).  Second, ENG expression (mRNA) has been found to be elevated in 
the cellular component of maternal blood during all three trimesters of pregnancy, as well as in 
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the placenta obtained via cesarean section before labor onset (Farina et al., 2010; Nishizawa et 
al., 2007; Purwosunu et al., 2009; Sekizawa et al., 2010).  Third, maternal genetic variation in 
ENG and TGFβR2 have been implicated in susceptibility to/protection from preeclampsia 
through genetic association studies; however, mechanisms that may explain these associations 
have not been defined (Bell et al., 2013).   
DNA methylation is a form of epigenetic regulation that can greatly affect gene 
expression and is a potential molecular mechanism that may explain the role of the endoglin 
pathway, including the genetic association between the ENG pathway, and susceptibility 
to/protection from preeclampsia.  In a small pilot study, differences in blood-based, genome-
wide DNA methylation profiles were detected during the first trimester in women who 
developed preeclampsia compared to women who had uncomplicated pregnancies, however, 
these differences were not detected in ENG or TGFβR2 (Anderson et al., 2014).  Several others 
studies have also evaluated DNA methylation profiles in maternal peripheral white blood cells 
using both candidate gene and genome-wide approaches.  The results of the studies by Anderson 
et al. (2014), Ge et al. (2015), White et al. (2013), White et al. (2016), and Ye et al. (2016), have 
generally shown that different genes display differences in DNA methylation in women with 
preeclampsia as compared to normotensive women, including genes that are hypomethylated and 
hypermethylated in preeclampsia.  However, when looking at DNA methylation in maternal 
peripheral blood as it relates to the development of preeclampsia, there is a lack of research 
specifically looking at methylation levels of ENG and TGFβR2.   
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2.0  PURPOSE 
The purpose of this observational pilot study was to determine if blood-based DNA methylation 
levels of ENG and TGFβR2 gene promoter regions differ significantly between women with 
clinically-overt preeclampsia compared to normotensive pregnant women. Therefore, the 
specific aim of this study was the following: 
Specific Aim: Compare maternal blood-based DNA methylation levels of the ENG 
and TGFβR2 gene promoters in women with clinically-overt preeclampsia to that in 
normotensive women.  DNA extracted from maternal peripheral blood will be used to detect 
methylation-levels of ENG and TGFβR2 gene promoters in cases (clinically-overt preeclampsia) 
and controls (normotensive pregnancies).  
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3.0  METHODS 
3.1 DESIGN 
A targeted, candidate gene methylation approach was used to interrogate and compare 
methylation status of ENG and TGFβR2 gene promoter CpG islands.  Samples and 
demographic/clinical data were received from the Prenatal Exposures and Preeclampsia (PEPP) 
study conducted at Magee-Womens Hospital of the University of Pittsburgh Medical Center, in a 
de-identified manner.  Participants were 1:1 frequency matched on gestational age that the 
sample was collected (+/- 2 weeks), nulliparity, smoking status, and labor status when the sample 
was collected, as these characteristics could impact methylation. ENG and TGFβR2 promoter 
DNA methylation levels in the blood of women with clinically-overt preeclampsia to women 
with uncomplicated pregnancies were compared.   
3.2 PARTICIPANTS 
This study was reviewed and approved by the University of Pittsburgh Human Research 
Protection Office.  Participants included in this study originally participated in the PEPP study, 
cohorts 1 and 2.  The purpose of PEPP was to investigate factors related to the development of 
preeclampsia.  Participants recruited for PEPP 1 and 2 were pregnant women between the ages of 
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14 and 44 years.  They were recruited either at 20 weeks’ gestation, or earlier, and were followed 
through delivery or they were recruited cross-sectionally during labor due to suspected 
preeclampsia.  Women were excluded from the PEPP study if they had a history of chronic renal 
disease, hypertension, diabetes, multi-fetal gestation, infection, or metabolic disorders—all of 
which are associated with an increased risk for preeclampsia.   
The participants included in this thesis project were self-reported Caucasian, including 
n=22 preeclampsia cases who were 1:1 frequency matched to n=22 normotensive controls on 
gestational age that the sample was collected (± 2 weeks), nulliparity, smoking status, and labor 
status when the sample was collected.  Cases were defined as having clinically overt 
preeclampsia when the samples were collected.  The diagnosis of preeclampsia was based on a 
research definition: (1) blood pressure ≥ 140 mmHG systolic and/or 90 mmHg diastolic after 20 
weeks’ gestation based on the average of the four most recent blood pressures taken in the 
hospital prior to therapeutic intervention; (2) proteinuria ≥ 300mg/24 hours, ≥ 0.3 
protein/creatinine ratio, ≥ 2+ on a random urine specimen, or ≥ 1+ on a catheterized urine 
specimen; and (3) hyperuricemia with serum uric acid concentration ≥ 1 standard deviation from 
normal for gestational age.  Controls were defined as women who remained normotensive 
throughout their entire pregnancy, without developing proteinuria and delivered healthy term 
babies.   
3.3 DNA EXTRACTION AND QUANTIFICATION 
Genomic DNA was extracted via protein precipitation from maternal peripheral blood samples 
that were collected during the third trimester.  De-identified DNA aliquots were provided by 
 8 
PEPP investigators to the principal investigator and her thesis advisor. Genomic DNA was 
quantified at the University of Pittsburgh Genomics Research Core.  
3.4 METHYLATION DATA COLLECTION 
Methylation data were collected using EpiTect Methyl II PCR Assays (Qiagen® Inc., 
Germantown, Maryland) after DNA quantification, and all participant samples were run in 
duplicate for both the ENG and TGFβR2 assays. The values were reviewed from these two 
rounds of data collection. If methylation data for a participant sample were generated for both 
rounds of data collection, and their methylation values were concordant (|Run 1 value (% 
methylated) – Run 2 value (% methylated)| ≤ 15% for both ENG and TGFβR2), the two 
methylation values were averaged. In the event that (1) methylation data for a participant sample 
were only generated for one of the two rounds of data collection or (2) methylation data 
generated for the first two rounds of data collection for a participant sample were discordant 
(|Run 1 value (% methylated) – Run 2 value (% methylated)| ≥ 15% for ENG and/or TGFβR2), 
the participant sample underwent a third round of data collection.  Samples that failed to generate 
data for the first two rounds of data collection were not included in the third round of data 
collection, and they were omitted from analysis. Only samples that had two concordant values 
were included in the final analysis, with the average of these two values used for analysis (Figure 
1).  
To begin methylation data collection, a reaction mix was first prepared using a volume of 
the samples derived from the DNA quantification (to achieve a DNA concentration of 
>4µg/mL), 5X Restriction Digestion Buffer, and RNase-/DNase-free water, for a total volume of 
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60µl per sample.  The reaction mix was prepared in 0.5mL microcentrifuge tubes and stored at -
20˚C.  A restriction digestion was then carried out using the reaction mixes.  The plates were set 
up so that each sample was combined separately with no enzyme in one well, a methylation-
sensitive restriction enzyme (MSRE) in another well, a methylation-dependent restriction 
enzyme (MDRE) in a third well, and a combination of MSRE and MDRE in the last well.  
RNase-/DNase-free water was then added to the entire plate for a total volume of 15µl per well.  
The sample plate was digested in a thermal cycler at 37˚C for 6 hours or overnight, and then at 
65˚C for 20 minutes. A polymerase chain reaction (PCR) was then set up using the digested 
product from the previous step and combined with PCR Master Mix (SYBR Green) (Applied 
BiosystemsTM, Foster City, California), PCR Primer Mix, and more RNase-/DNase-free water.  
Each sample was run with two different primer mixes: EpiTect Methyl II PCR Primer Assay for 
Human ENG (CpG Island 114642; Catalogue number: EPHS114642-1A; Qiagen® Inc., 
Germantown, Maryland) in one plate, and EpiTect Methyl II PCR Primer Assay for Human 
TGFβR2 (CpG Island 110111; Catalogue number: EPHS110111-1A; Qiagen® Inc., 
Germantown, Maryland) in another plate.  The PCR was run in the 7000 Sequence Detection 
System (Applied BiosystemTM, Foster City, California) using an absolute quantification 
(standard curve) data collection setting.  The EpiTect Methyl II Assay Handbook indicates the 
following: the product digested with no enzyme represents total input DNA for PCR detection; 
the MSRE digests unmethylated and partially methylated DNA and hypermethylated DNA is 
detected with PCR; the MDRE digests methylated DNA and the unmethylated DNA is detected 
with PCR; and the MSRE-MDRE combination should digest all DNA molecules (Qiagen, 2012).  
Tables 1-5 detail each step of the methylation data collection protocol.   
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Table 1. Methylation Data Collection Step 1: Preparing Reaction Mix 
DNA (125 ng) Volume based on DNA concentration of samplea 
5X Restriction Digestion Buffer 13µl 
RNase-/DNase-free water Volume dependent on amount of DNA 
Total Volume: 60µl 
Notes.Table adapted from EpiTect Methyl II PCR Assay Handbook (Qiagen, 2012). aThe 
recommended DNA concentration is > 4µg/mL (Qiagen, 2012). 
 
 
Table 2. Methylation Data Collection Step 2: Restriction Digestion 
 M0 (A) MS (C) MD (E) MS+D (G) 
Reaction Mix (Step 1)a 14µl 14µl 14µl 14µl 
MSRE X 0.5µl X 0.5µl 
MDRE X X 0.5µ1 0.5µ1 
RNase-/DNase-free water 1µl 0.5µl 0.5µ1 X 
Total Volume: 15µl 15µl 15µl 15µl 
Notes. Table adapted from EpiTect Methyl II PCR Assay Handbook (Qiagen, 2012). 
 aMixture from Methylation Data Collection Step 1. M0(A)= No restriction enzyme, plate 
 row A. MS(C)= Methylation sensitive enzyme, plate row C. MD(E)= Methylation 
 dependent enzyme, plate row E. MS+D(G)= Methylation sensitive and dependent 
 enzymes, plate row G. MSRE= Methylation-Sensitive Restriction Enzyme. MDRE= 
 Methylation-Dependent Restriction Enzyme.  
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Table 3. Methylation Data Collection Step 3: Polymerase Chain Reaction (PCR) Setup 
 M0 (A) MS (C) MD (E) MS+D (G) 
PCR Master Mix (SYBR Green) 12.5µl 12.5µl 12.5µl 12.5µl 
PCR Primer Mix (ENG or TGFβR2) 1µl 1µl 1µl 1µl 
M0 Digest 5µl X X X 
MS Digest  X 5µl X X 
MD Digest X X 5µl X 
MS+D Digest X X X 5µl 
RNase/DNase-free water 6.5µl 6.5µl 6.5µl 6.5µl 
Total Volume:  25µl 25µl 25µl 25µl 
Notes. Table adapted from EpiTect Methyl II PCR Assay Handbook (Qiagen, 2012). 
 M0(A)= No restriction enzyme, plate row A. MS(C)= Methylation sensitive enzyme, plate 
 row C.  MD(E)= Methylation dependent enzyme, plate row E. MS+D(G)= Methylation 
 sensitive and dependent enzymes, plate row G. M0 Digest= Product from Methylation 
 Data Collection Step 2, row A. MS Digest= Product from Methylation Data Collection 
 Step 2, row C. MD Digest= Product from Methylation Data Collection Step 2, row E. 
 MS+D Digest= Product from Methylation Data Collection Step 2, row G.  
 
    Table 4. Thermal Cycler Protocol: Incubation for Restriction Digestion 
Stage 1 37˚C 6 hours or overnight 
Stage 2 65˚C 20 minutes 
Notes. Table adapted from EpiTect Methyl II PCR Assay Handbook (Qiagen, 2012). 
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      Table 5. PCR Cycling Protocol (7000 Sequence Detection System) 
Stage 1 Step 1 95˚C 10min 1 cycle 
 Step 1  99˚C 30sec  
Step 2 72˚C 1min 
 Step 1 97˚C 15sec  
Step 2 72˚C 1mina 
Notes. Table adapted from EpiTect Methyl II PCR Assay Handbook (Qiagen, 2012).  
 aData collection occurs during Step 2 of Stage 3.  
3.5 RATIONALE FOR FINAL SAMPLE SIZE 
Throughout the study, several participants were eliminated from the analysis for various reasons.  
Initially, two participants were omitted, as they were not nulliparous.  A third participant was 
later omitted due to a misclassification of pregnancy outcome.  These omissions resulted in a 
sample size of N=41, with n=20 cases and n=21 controls.  Methylation data was collected for all 
samples in duplicate, then any samples that had two disparate values or only one value from the 
first two runs of data collection, underwent a third round of data collection.  The data collected 
were reviewed, and any samples that either (1) failed both of the first two data collection rounds, 
(2) generated data for only one round of data collection, (3) or generated discordant data values 
that differed by more than 15%, were omitted from the final analysis.  The final analysis 
included N= 35 participants (18 cases, 17 controls) for demographic data, N= 20 participants (9 
cases, 11 controls) for ENG methylation data, and N=28 participants (15 cases, 13 controls) for 
TGFβR2 methylation data.  
Stage 2 
 
3 cycles 
40 cycles Stage 3 
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Figure 1. Sample Size Flowchart 
Notes. aParticipants were omitted for one of the following reasons: Could not obtain methylation 
values for two rounds of data collection, could never obtain values, or the two values were 
disparate, when run with both ENG and TGFβR2.  
3.6 STATISTICAL ANALYSIS 
The data were analyzed using IBM’s SPSS Statistics Version 24 software (IBM Corp., Armonk, 
New York).  Our main outcome of average methylation levels was evaluated using bivariate 
analysis, comparing values between cases and controls represented as percentages.  Continuous 
demographic/clinical variables were analyzed either using the parametric Independent Samples t-
test or the non-parametric Mann-Whitney U Test, depending on whether the variables were 
normally distributed.  Categorical demographic/clinical variables were analyzed using the 
Pearson Chi-Square test.  We were unable to control for potential confounders in multivariate 
analysis due to the small sample size.  
Omit 6;  Data 
Collection 
Issues for both 
ENG and 
TGFβR2a 
Omit 1; 
Pregnancy 
Outcome 
Misclassified 
  
 
Omit 2; 
para ≠ 0 
 
TGFβR2 
N = 28 
(15 cases, 13 
controls) 
 
ENG 
N = 20 
(9 cases, 11 
controls) 
 
N = 35 
 
(18 cases, 17 
controls) 
 
N = 41 
 
(20 cases, 21 
controls) 
 
N = 42 
 
(21 cases, 21 
controls) 
 
N = 44 
 
(22 cases, 22 
controls) 
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4.0  RESULTS 
4.1 DEMOGRAPHIC/CLINICAL CHARACTERISTICS 
Several characteristics were found to be similar between participants with clinically-overt 
preeclampsia and normotensive control participants (Table 6). All participants were self-reported 
Caucasian and nulliparous.  Gestational age at sample collection was similar between groups, 
which was expected given that the cases and controls were 1:1 frequency matched on gestational 
age at sample collection, with the majority of samples not being collected in labor. Furthermore, 
cases and controls were similar with respect to maternal age, gestational age at delivery (Cases 
(M(SD)): 37.56(2.95); Controls (M(SD)): 39.4(1.15)), and smoking status.  The majority of 
participants were non-smokers (Cases: 55.6%; Controls: 58.8%).  Average systolic blood 
pressure before 20 weeks’ gestation was also similar between cases and controls.  Additionally, 
frequency matching remained the same for both subsets that were analyzed for ENG and 
TGFβR2 methylation after samples were omitted (data not shown).  
Participants with clinically-overt preeclampsia and normotensive control participants also 
differed in regard to several characteristics (Table 6). Average diastolic blood pressure before 20 
weeks’ gestation was significantly higher in cases compared to controls (although the blood 
pressure ranges were within normal limits).  Both average systolic and diastolic blood pressure 
measurements during labor were significantly higher in cases compared to controls—an expected 
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finding given the research definition and clinical presentation of preeclampsia.  Average plasma 
sENG levels were significantly higher in cases (Cases [M±(SD)]= 31.5ng/mL ± 21.03; Controls= 
10.5ng/mL ± 4.86), which demonstrates a similar trend to the study completed by Levine et al. 
(2006).  Pre-pregnancy body mass index (BMI) was found to be significantly different between 
groups, with cases having higher BMIs than controls, which was expected given the increased 
risk of preeclampsia that is associated with obesity (Anderson & Schmella, 2017; Durst, Tuuli, 
Stout, Macones, & Cahill, 2016).  
Table 6. Demographic/Clinical Characteristics 
Variables Cases (n=18) Controls (n=17) p-Value 
Maternal age, years (M(SD)) 29.5(6.08) 27.76(6.02) 0.402a 
Gestational age at delivery, weeks (M(SD)) 37.56(2.95) 39.4(1.15) 0.057b 
Gestational age at sample collection, weeks 
(M(SD)) 
37.45(2.99) 37.24(3.26) 0.791b 
Average SBP <20wks, mmHg (M(SD)) 115.94(9.4) 112.65(7.91) 0.277a 
Average DBP <20wks, mmHg (M(SD)) 72.41(4.93) 67.65(5.71) 0.014a 
Average SBP in labor, mmHg (M(SD)) 152.11(10.48) 118.65(11.7) <0.001a 
Average DPB in labor, mmHg (M(SD)) 90.22(6.84) 70.24(8.45) <0.001a 
Pre-pregnancy BMI, kg/m2 (M(SD)) 29.32(6.71) 24.5(6.54) 0.039a 
Average plasma sENG, ng/mL (M(SD)) 31.5(21.03) 10.5(4.86) <0.001b 
Caucasian (n(%)) 18(100%) 17(100%) N/A 
Nulliparous (n(%)) 18(100%) 17(100%) N/A 
Smoking Status (n(%))                            No 10(55.6%) 10(58.8%) 0.845c 
Sample Collected in Labor (n(%))         No 12(66.7%) 11(64.7%) 0.903c 
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Note. M(SD)= mean (standard deviation). SBP= systolic blood pressure. DBP= diastolic blood 
pressure. mmHg= millimeters of mercury. BMI=body mass index. aIndependent samples t-test. 
bMann-Whitney U test. cPearson Chi-Square test. 
4.2 ENG AND TGFΒR2 METHYLATION RESULTS 
Participants with clinically-overt preeclampsia were found to have higher levels of DNA 
methylation with respect to the CpG island promoter region of ENG compared to controls, but 
this difference was not statistically significant (Table 7).  The CpG island in the promoter region 
of TGFβR2 was also not differentially methylated between cases and controls (Table 7).  
Methylation results for both ENG and TGFβR2 were not normally distributed, which is why a 
non-parametric analytic approach was used.  For ENG, the minimum percent methylated value 
among cases was 2.24%, with a maximum percent methylated value of 17.46%; among controls, 
the minimum percent methylated value was 1.65% and the maximum percent methylated value 
was 19.3%.  For TGFβR2, the minimum percent methylated value among cases was 0.01% and 
the maximum percent methylated value was 5.24%; among controls, the minimum percent 
methylated value was 0.19% and the maximum percent methylated value was 4.22%. 
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Table 7. ENG & TGFβR2 Methylation Results  
 
ENG,  
% Methylated                                                                  
 
 
M(SD) 
 
Median(IQR) 
Cases(n=9) Controls(n=11) p-value 
6.54(4.57) 
5.2(3.57, 7.86) 
4.81(5.08) 
 
2.72(2.38, 6.04) 
 
0.102a 
 
TGFβR2, 
% Methylated 
 
M(SD) 
 
Median(IQR) 
Cases(n=15) Controls(n=13)  p-value 
1.5(1.37) 
 
1.5(0.2, 2.12) 
1.7(1.4) 
 
1.51(0.48, 2.64) 
 
0.695a 
Note. M(SD)= mean (standard deviation). Median(IQR)= median (inter-quartile range). aMann-
Whitney U test.  
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5.0  DISCUSSION 
This observational, pilot study was designed to investigate if blood-based DNA methylation 
levels of ENG and TGFβR2 gene promoter regions differ significantly between women with 
clinically-overt preeclampsia compared to normotensive pregnant women, as methylation may 
represent a potential mechanism explaining the pathway’s role in preeclampsia.  Neither of the 
CpG islands within the promoter regions of ENG and TGFβR2 were found to be differentially 
methylated between women with clinically-overt preeclampsia and women with normotensive, 
uncomplicated pregnancies. These findings could indicate that there is no relationship between 
methylation of these promoters and the presence or absence of clinically-overt preeclampsia; 
however, this pilot study may have been underpowered to detect statistically significant 
differences when they truly existed. As such, additional studies with larger sample sizes are 
needed to further investigate the association between ENG pathway methylation and 
preeclampsia.   
     When designing epigenetic studies, there are important factors to consider that can 
impact the collection and interpretation of methylation data: (1) tissue type, (2) cell type 
heterogeneity, and (3) environment/demographic/clinical characteristics.  Methylation levels 
differ by tissue type and most studies related to methylation profiles in preeclampsia have been 
conducted in the placenta, with few exploring methylation in the blood. Blood is not the most 
proximal tissue to study for this phenotype; however, identifying a biomarker for preeclampsia in 
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the blood would advance the detection and management of this disease because blood is an 
accessible tissue.  Additionally, previous studies conducted with white blood cells have 
demonstrated a difference in DNA methylation between women with preeclampsia and 
normotensive women.  A limitation of these previous studies, as well as our pilot study, includes 
not correcting for cell type heterogeneity (Anderson et al., 2014; White et al., 2013; White et al., 
2016).  It is known that white blood cell proportions change across pregnancy and differ among 
women with and without preeclampsia, due to the inflammatory response present during normal 
pregnancy that is exaggerated during preeclampsia. As such, not controlling for this could impact 
the interpretation/validity of one’s results (Abbassi-Ghanavati, Greer, & Cunningham, 2009; 
Gabbe et al., 2017; Sacks, Studena, Sargent, & Redman, 1997).  It will be important to look 
further into the role of ENG in white blood cells in the setting of the maternal circulation.     
BMI, smoking, and gestational age are other factors that can also impact methylation. 
The difference in BMI between cases and controls was significant, with cases having higher pre-
pregnancy BMIs than controls.  Obesity increases the risk of developing preeclampsia and could 
impact methylation results (Anderson & Schmella, 2017; Durst et al., 2016).  Smoking has also 
been shown to impact methylation (Giannakou, Evangelou, & Papatheodorou, 2017; Zeilinger, 
2013).  Methylation status has also been shown to vary in the placenta with respect to gestational 
age (Leavey, et al., 2018). However, due to the small sample size, we were unable to use 
multivariate modeling to control for this variability.    
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5.1 STRENGTHS AND LIMITATIONS 
There were several strengths and limitations associated with this study.  Matching on certain 
characteristics that could impact methylation (gestational age at sample collection, nulliparity, 
smoking status, and labor status at sample collection) was one strength of this study. The cases of 
this study were labeled as such based on a strict phenotype definition of preeclampsia, while the 
controls were also based on a strict phenotype definition.  Furthermore, a major strength was our 
ability to collect methylation data in duplicate for each sample, and then a third time for any 
samples that needed to make-up for any failed runs or disparate results.     
The small sample size was a main limitation of this study.  We started with 22 cases and 
22 controls, but we ended up with 18 cases and 17 controls due to a discrepancy in demographic 
data or failure to collect consistent methylation values.  The small sample size further prohibited 
the use of multivariate modeling in which the effects of potential confounders on methylation 
could be accounted for. Additionally, the sample was all self-reported Caucasian, limiting the 
generalizability of findings, and we were unable to control for cell type heterogeneity, which 
could impact the validity of our results.   
5.2 CONCLUSION AND FUTURE DIRECTIONS 
This observational, pilot study was unable to detect a significant association between DNA 
methylation ENG pathway gene promoters and preeclampsia. The underlying mechanism(s) of 
preeclampsia is/are still not understood; however, previous research points to DNA methylation 
as a form of epigenetic regulation affecting gene expression and a potential molecular 
 21 
mechanism explaining this association.  Future studies that include a larger sample size, control 
for cell type heterogeneity, and control for potential confounders, are needed to validate previous 
findings.  Exploring methylation profiles of other genes and gene pathways affecting vascular 
formation/function and placental implantation, and their association with preeclampsia 
development, should also be considered in future studies.  Genes with significant variation in 
methylation have the potential to serve as blood-based biomarkers, differentiating preeclampsia 
from normotensive pregnancy and improving evidenced-based screening and treatment for these 
women.             
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